TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27906598

Group type: EXPERIMENTAL
Intervention: Supplemental O2 with oral dexamethasone 8 mg q8 hours
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Supplemental O2 with sustained release oral nifedipine 20 mg q8 hours
Number of subjects: 133

Group type: COMPARATOR
Intervention: Only supplemental O2
Number of subjects: 133
Study: 24587571

Group type: EXPERIMENTAL
Intervention: Zolpidem 3.5 mg (ZST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22747095

Group type: EXPERIMENTAL
Intervention: EMPowerplus™ (EMP+)
Number of subjects: 10
Study: 20307353

Group type: EXPERIMENTAL
Intervention: Intervention 1 (60 g WG/d for 16 weeks)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Intervention 2 (60 g WG/d for 8 weeks followed by 120 g WG/d for 8 weeks)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control (no dietary change)
Number of subjects: 316
Study: 18559985

Group type: EXPERIMENTAL
Intervention: Tertatolol (beta-adrenergic receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-AR antagonist)
Number of subjects: 0
Study: 15774609

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (matched healthy individuals)
Number of subjects: 53
Study: 12006443

Group type: EXPERIMENTAL
Intervention: NIPPV via mouthpiece
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NIPPV with ventilators
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unencumbered walks (breathing normally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ventilator-assisted walks
Number of subjects: 8
Study: 10484947

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 67
Study: 8604368

Group type: EXPERIMENTAL
Intervention: Retention control training (RCT) for younger children (aged 4 to 5 years)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retention control training (RCT) for older children (aged 7 to 8 years)
Number of subjects: 30
Study: 2008547

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 7038977

Group type: EXPERIMENTAL
Intervention: Ancrod (daily subcutaneous injections)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 73
Study: 31480676

Group type: EXPERIMENTAL
Intervention: Whey Protein (WG) 40 g/day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hydrolysed Collagen (CG) 38 g/day
Number of subjects: 37
Study: 28864705

Group type: EXPERIMENTAL
Intervention: High‐intensity impact loading exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High‐intensity resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home‐based 'positive' control group
Number of subjects: 0
Study: 26765515

Group type: EXPERIMENTAL
Intervention: Feedback group (provided with activity and sleep data during each HD treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tracking device
Number of subjects: 29
Study: 25258158

Group type: EXPERIMENTAL
Intervention: CardioGard Emboli Protection cannula
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard aortic cannula
Number of subjects: 66
Study: 22803426

Group type: EXPERIMENTAL
Intervention: Ligustrazine Injection (LI) 2 mg/kg given by intravenous dripping 30 min before autologous blood collection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no Ligustrazine Injection)
Number of subjects: 60
Study: 20070414

Group type: EXPERIMENTAL
Intervention: Personalized risk reports, booklets on alcohol-associated risks, and advice from physicians, followed by a health educator call
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Concern about alcohol-related risks
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Reading through the educational booklet
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Perception that physicians discussed risks and advised changing drinking behaviors
Number of subjects: 239
Study: 18039195

Group type: EXPERIMENTAL
Intervention: Fixed combination inhalers containing F/S
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral or parenteral corticosteroids (7-14 days) and other medications (retrospective group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral or parenteral corticosteroids (7-14 days) and other medications (prospective group)
Number of subjects: 70
Study: 16145022

Group type: EXPERIMENTAL
Intervention: Heavy call
Number of subjects: 34

Group type: COMPARATOR
Intervention: Light call with alcohol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Heavy call with placebo
Number of subjects: 34
Study: 12098499

Group type: EXPERIMENTAL
Intervention: Laser acupuncture at the left foot (Bladder 67)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dummy acupuncture (placebo stimulation)
Number of subjects: 10
Study: 10407199

Group type: EXPERIMENTAL
Intervention: Correlated motion in random dot kinematograms (RDK) with varying percentages of correlated moving pixels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncorrelated motion in random dot kinematograms (RDK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coherent motion direction preceded by uncorrelated motion in RDKs
Number of subjects: 0
Study: 1417008

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 400 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 + Carboplatin (CBDCA) 350 mg/m2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone
Number of subjects: 15
Study: 3857335

Group type: EXPERIMENTAL
Intervention: Mandibular repositioning treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat plane occlusal splint treatment
Number of subjects: 20
Study: 31042410

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) with lymphoscintigraphy (LSG)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB) without lymphoscintigraphy (LSG)
Number of subjects: 1198
Study: 29861388

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg for 16 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (matched participants without MC4R mutation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 42
Study: 26596899

Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG; boxing game on Xbox Kinect 360)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise (EX; cycling)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Passive Video Game (PVG; boxing game on Xbox 360)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON; sitting)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hunger and satiety measures
Number of subjects: 24
Study: 26061836

Group type: EXPERIMENTAL
Intervention: Mobile-phone positioning system dispatching trained lay volunteers to patients nearby (intervention group)
Number of subjects: 9828

Group type: COMPARATOR
Intervention: No dispatch of trained lay volunteers (control group)
Number of subjects: 9828
Study: 23756654

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Diet + exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study: 21535135

Group type: EXPERIMENTAL
Intervention: Audilex training (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control game playing (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Audilex
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 19061675

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha plus ribavirin (peg‐IFNalpha/RBV) treatment for 48 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 17333800

Group type: EXPERIMENTAL
Intervention: Foley catheter without traction
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Foley catheter with traction
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal tablets
Number of subjects: 258
Study: 15692263

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet (MD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Red wine supplementation with MD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Red wine supplementation with both diets
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 21
Study: 10725066

Group type: EXPERIMENTAL
Intervention: Filtration leucocytapheresis (LCP)
Number of subjects: 25
Study: 9452848

Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine (40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (2 ml 0.5%)
Number of subjects: 40
Study: 7639022

Group type: EXPERIMENTAL
Intervention: Total intravenous ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional anaesthesia (halothane, nitrous oxide, and relaxant)
Number of subjects: 0
Study: 3286166

Group type: COMPARATOR
Intervention: Constant insulin infusion (0.175 mU/kg.min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin delivery (2.1 mU/kg at 12-min intervals)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both constant and pulsatile insulin delivery
Number of subjects: 7
Study: 28867520

Group type: EXPERIMENTAL
Intervention: iAssist guidance system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 50
Study: 24721637

Group type: COMPARATOR
Intervention: 1-day Acuvue(®) clear SCL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1-day Acuvue(®) Define(TM) tinted SCL
Number of subjects: 16
Study: 23817279

Group type: EXPERIMENTAL
Intervention: Positive emotional expression influenced by time of day (RR = 1.05) and impaired mobility (RR = 1.37)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Negative emotional expression influenced by gender (RR = 1.85), age (RR = 1.03), and education (RR = 0.54)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three trajectory groups for positive emotional expression: low stable, fluctuating afternoon peaking, and fluctuating morning peaking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two trajectory groups for negative emotional expression: consistent pattern and inconsistent pattern
Number of subjects: 30
Study: 20497439

Group type: COMPARATOR
Intervention: Flapless group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: COMPARATOR
Intervention: BSG group
Number of subjects: 52
Study: 18769863

Group type: EXPERIMENTAL
Intervention: Prednisone and famciclovir (P+F group)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Prednisone alone (P group)
Number of subjects: 167
Study: 16637747

Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) measuring automatic fear associations in spider fearful participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit Association Test (IAT) measuring automatic fear associations in nonfearfuls and spider enthusiasts
Number of subjects: 0
Study: 12643608

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (H. pylori negative with no mucosal lesions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (H. pylori negative with lesions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (H. pylori positive with lesions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (H. pylori negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib (in vitro biopsy incubation)
Number of subjects: 0
Study: 10827333

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (OC) containing ethinyl estradiol 20 microg and 0.1 mg levonorgestrel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lunelle (injectable contraceptive containing estradiol cypionate 5 mg and medroxyprogesterone acetate 25 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (OC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lunelle
Number of subjects: 30
Study: 8863203

Group type: EXPERIMENTAL
Intervention: Benomyl (Benlate 50 DF) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exposure to benomyl (control group)
Number of subjects: 0
Study: 1487095

Group type: EXPERIMENTAL
Intervention: Two-band compressor (condition C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Linear amplifier (condition L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hearing aids normally worn (condition Own)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Without hearing aids (condition U)
Number of subjects: 20
Study: 2982563

Group type: EXPERIMENTAL
Intervention: Low-dose antacid gel (6 X 12 ml/d; neutralisation capacity 120 mmol)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cimetidine (1 g/d)
Number of subjects: 125
Study: 30560740

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 42
Study: 30400138

Group type: EXPERIMENTAL
Intervention: Cooked B. carinata
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Raw B. carinata
Number of subjects: 22
Study: 27209068

Group type: EXPERIMENTAL
Intervention: Person-centered progressive resistance exercise performed twice a week for 15 weeks
Number of subjects: 67
Study: 25493671

Group type: EXPERIMENTAL
Intervention: Chlorhexidine antimicrobial dressing
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gauze and micro porous tape
Number of subjects: 85
Study: 22908836

Group type: EXPERIMENTAL
Intervention: 1.5 atm abs (breathing 100% oxygen)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.2 atm abs (breathing air)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pressure changes (1.2 atm abs and 1.5 atm abs)
Number of subjects: 42
Study: 20234324

Group type: EXPERIMENTAL
Intervention: Monoaxial screw insertion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Polyaxial screw insertion
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Head-shaft angle < 130 degrees
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Head-shaft angle > 130 degrees
Number of subjects: 66
Study: 18074484

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 2580

Group type: COMPARATOR
Intervention: Heated humidifiers (HHs)
Number of subjects: 2580
Study: 15752388

Group type: EXPERIMENTAL
Intervention: cAAI-guided propofol infusion (Group G, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional clinical practice (Group C, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cAAI values in Group G
Number of subjects: 20

Group type: COMPARATOR
Intervention: cAAI values in Group C
Number of subjects: 20
Study: 12027841

Group type: EXPERIMENTAL
Intervention: Sevoflurane titration with A‐line auditory guidance (target auditory evoked potential index of 30+/‐5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane titration clinically (without AEP guidance)
Number of subjects: 60
Study: 10439477

Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 0.17 mg total hypericin per day (114 patients)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 0.33 mg total hypericin per day (115 patients)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 1 mg total hypericin per day (119 patients)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 348
Study: 7852667

Group type: EXPERIMENTAL
Intervention: Azelastine (0.56 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2181434

Group type: COMPARATOR
Intervention: Tamoxifen (exact dosage not specified)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (exact dosage not specified)
Number of subjects: 140
Study: 322794

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cholestyramine (doubled dose)
Number of subjects: 10
Study: 31201191

Group type: EXPERIMENTAL
Intervention: STHLM3 test and MRI-targeted biopsies
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Prostate-specific antigen (PSA) and systematic biopsies
Number of subjects: 10000
Study: 27693443

Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal exercise clothes (Control)
Number of subjects: 15
Study: 25896891

Group type: EXPERIMENTAL
Intervention: RVOT septal pacing
Number of subjects: 80

Group type: COMPARATOR
Intervention: RVAP
Number of subjects: 80
Study: 23871349

Group type: EXPERIMENTAL
Intervention: Periprocedural anticoagulation
Number of subjects: 635
Study: 21586127

Group type: EXPERIMENTAL
Intervention: Early surgical evacuation of the haematoma within 12 hours
Number of subjects: 600

Group type: COMPARATOR
Intervention: Initial conservative treatment
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Early surgical evacuation
Number of subjects: 600
Study: 19710593

Group type: EXPERIMENTAL
Intervention: Etravirine (200 mg twice daily)
Number of subjects: 1203
Study: 16794492

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1484
Study: 12636120

Group type: EXPERIMENTAL
Intervention: Peroxide and light
Number of subjects: 87

Group type: COMPARATOR
Intervention: Peroxide control (peroxide gel)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Light control (placebo gel and light)
Number of subjects: 87
Study: 10992827

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Metamizol (1.2 g)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:1 ratio
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:0.3 ratio
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:3 ratio
Number of subjects: 101
Study: 9109909

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1609380

Group type: EXPERIMENTAL
Intervention: 12 minute protocol with two sudden bursts of three minute high intensity exercise, preceded by three minutes of low level exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Conventional three minute incremental test lasting 12 minutes
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Initial burst of high intensity exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 19
Study: 3903736

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 31808664

Group type: EXPERIMENTAL
Intervention: Fixed SVV fluid strategy group (n=57)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Individual SVV group (n=61)
Number of subjects: 118
Study: 30395050

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.49 ± 0.44 g·kg·d for oxidation (Ox)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.53 ± 0.32 g·kg·d for net protein balance (NB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Protein intake (0.2-2.9 g·kg·d)
Number of subjects: 8
Study: 27601060

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 3722
Study: 27618886

Group type: EXPERIMENTAL
Intervention: Topical betuline gel (TBG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 220
Study: 25842575

Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Number of subjects: 42
Study: 22234041

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing n-3 polyunsaturated fatty acids (2 cans/day, 2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing n-3 polyunsaturated fatty acids
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isocaloric control supplement
Number of subjects: 40
Study: 20194829

Group type: EXPERIMENTAL
Intervention: Combined treatment (CBGT + phenelzine)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 17322426

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg b/d)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg t.d.s)
Number of subjects: 250
Study: 15662518

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical antipsychotic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-free patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 11900994

Group type: EXPERIMENTAL
Intervention: Lovastatin (10-60 mg once-daily doses of a controlled-release formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 0
Study: 9990816

Group type: EXPERIMENTAL
Intervention: 2 x 500 mg clarithromycin + 2 x 1000 mg amoxicillin + 40 mg pantoprazole/day for 7 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 2 x 500 mg clarithromycin + 2 x 400 mg ranitidine bismuth citrate/day for 14 days
Number of subjects: 99